Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Strecker

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Clinical Chemistry and Laboratory Medicine|August 2, 2012
Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogensThomas Strecker, Jennifer Uhlendorff, Sandra Diederich, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2015
Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection During an Outbreak EmergencyThomas Strecker, Bernadett Palyi, Heinz Ellerbrok, et al.
The Journal of Infectious Diseases|November 2, 2016
Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus InfectionChristine Dahlke, Sebastian Lunemann, Rahel Kasonta, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responsesPhilip J M Brouwer, Hailee R Perrett, Tim Beaumont, et al.
The Journal of Infectious Diseases|October 12, 2019
Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy AdultsLouis Fries, Iksung Cho, Verena Krähling, et al.
Scientific Reports|September 2, 2020
Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodiesKimberley Steeds, Yper Hall, Gillian S Slack, et al.
Frontiers in Immunology|May 2, 2022
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and PathogenesisJack Mellors, Tom Tipton, Sarah Katharina Fehling, et al.
The Journal of Infectious Diseases|July 9, 2018
Serological Evidence for the Circulation of Ebolaviruses in Pigs From Sierra LeoneKerstin Fischer, Juliet Jabaty, Roland Suluku, et al.
The Journal of Infectious Diseases|December 31, 2015
Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus InfectionStuart David Dowall, Jo Callan, Antra Zeltina, et al.
NPJ Vaccines|August 18, 2020
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activityHelena Müller, Sarah Katharina Fehling, Jens Dorna, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Clinical Chemistry and Laboratory Medicine|August 2, 2012
Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogensThomas Strecker, Jennifer Uhlendorff, Sandra Diederich, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 21, 2015
Field Evaluation of Capillary Blood Samples as a Collection Specimen for the Rapid Diagnosis of Ebola Virus Infection During an Outbreak EmergencyThomas Strecker, Bernadett Palyi, Heinz Ellerbrok, et al.
The Journal of Infectious Diseases|November 2, 2016
Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus InfectionChristine Dahlke, Sebastian Lunemann, Rahel Kasonta, et al.
Biorxiv : the Preprint Server for Biology|January 8, 2024
Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responsesPhilip J M Brouwer, Hailee R Perrett, Tim Beaumont, et al.
The Journal of Infectious Diseases|October 12, 2019
Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy AdultsLouis Fries, Iksung Cho, Verena Krähling, et al.
Scientific Reports|September 2, 2020
Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodiesKimberley Steeds, Yper Hall, Gillian S Slack, et al.
Frontiers in Immunology|May 2, 2022
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and PathogenesisJack Mellors, Tom Tipton, Sarah Katharina Fehling, et al.
The Journal of Infectious Diseases|July 9, 2018
Serological Evidence for the Circulation of Ebolaviruses in Pigs From Sierra LeoneKerstin Fischer, Juliet Jabaty, Roland Suluku, et al.
The Journal of Infectious Diseases|December 31, 2015
Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus InfectionStuart David Dowall, Jo Callan, Antra Zeltina, et al.
NPJ Vaccines|August 18, 2020
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activityHelena Müller, Sarah Katharina Fehling, Jens Dorna, et al.
Pageof 13